Compare Equinix Inc (EQIX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinix Inc vs 10X Genomics Inc — how do they compare? Equinix Inc trades at $1,026.06 (market cap $99.77B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: Equinix Inc is far larger — about 9.9× 10X Genomics Inc's market cap, and Equinix Inc pays a 2.04% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinix Inc for 110 Days and 10X Genomics Inc for 91 Days on average.
| EQIX | TXG | |
|---|---|---|
Market Cap | $99.77B | $10.07B |
Volume | 480,425 | 5,657,286 |
Sector | Real Estate | Health |
52-Week High | $1.12K | $97.74 |
52-Week Low | $726.09 | $11.48 |
Typical Hold Time | 110 Days | 91 Days |
Enterprise Value | $120.90B | $9.59B |
Dividend Yield | 2.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinix (EQIX) trades at $1,011.16, down 2.0% on the day amid a bearish technical signal. The stock shows strong fundamentals with revenue growth to $9.22B in 2025 and a net income margin of 15.63%, though valuation ratios like a P/E of 65.07 appear elevated. Recent earnings have been mixed, with Q2 2026 beating expectations but Q1 and Q4 2025 missing. Analyst sentiment remains bullish with a $1,250 consensus price target, supported by strong AI-driven data center demand highlighted in recent news.
The outlook for EQIX is positive due to robust AI infrastructure demand and a solid dividend, but risks include high capital expenditures and debt levels. Investors should weigh growth potential against valuation concerns and execution risks in a competitive sector.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
